Diabetes Care, Vol 23, Issue 11 1660-1665, Copyright © 2000 by American Diabetes Association

ARTICLES

Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes

ES Horton, C Clinkingbeard, M Gatlin, J Foley, S Mallows and S Shen
Joslin Diabetes Center, Boston, Massachusetts 02215, USA. edward.horton@joslin.harvard.edu

OBJECTIVE: To evaluate the efficacy and tolerability of nateglinide and metformin alone and in combination in type 2 diabetic patients inadequately controlled by diet, focusing on changes in HbA1c, fasting plasma glucose (FPG), and mealtime glucose excursions. RESEARCH DESIGN AND METHODS: In this randomized double-blind study, patients with an HbA1c level between 6.8 and 11.0% during a 4-week placebo run-in received 24 weeks' treatment with 120 mg nateglinide before meals (n = 179), 500 mg metformin three times a day (n = 178), combination therapy (n = 172), or placebo (n = 172). HbA1c and FPG were evaluated regularly, and plasma glucose levels were determined after Sustacal challenge at weeks 0, 12, and 24. Hypoglycemia and other adverse events were recorded. RESULTS: At study end point, HbA1c was reduced from baseline with nateglinide and metformin but was increased with placebo (-0.5, -0.8, and +0.5%, respectively; P < or = 0.0001). Changes in FPG followed the same pattern (-0.7, -1.6, and +0.4 mmol/l; P < or = 0.0001). Combination therapy was additive (HbA1c -1.4% and FPG -2.4 mmol/l; P < or = 0.01 vs. monotherapy). After Sustacal challenge, there was a greater reduction in mealtime glucose with nateglinide monotherapy compared with metformin monotherapy or placebo (adjusted area under the curve [AUC]0-130 min -2.1, -1.1, and -0.6 mmol x h(-1) x l(-1); p < or = 0.0001). An even greater effect was observed with combination therapy (AUC0-130 min -2.5 mmol x h(-1) x l(-1); P < or = 0.0001 vs. metformin and placebo). All regimens were well tolerated. CONCLUSIONS: Nateglinide and metformin monotherapy each improved overall glycemic control but by different mechanisms. Nateglinide decreased mealtime glucose excursions, whereas metformin primarily affected FPG. In combination, nateglinide and metformin had complementary effects, improving HbA1c, FPG, and postprandial hyperglycemia.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E. Selvin, S. Bolen, H.-C. Yeh, C. Wiley, L. M. Wilson, S. S. Marinopoulos, L. Feldman, J. Vassy, R. Wilson, E. B. Bass, et al. Cardiovascular Outcomes in Trials of Oral Diabetes Medications: A Systematic Review Arch Intern Med, October 27, 2008; 168(19): 2070 - 2080. [Abstract] [Full Text] [PDF]

				M. J. Abrahamson A 74-Year-Old Woman With Diabetes JAMA, January 10, 2007; 297(2): 196 - 204. [Abstract] [Full Text] [PDF]

				S. Nagamatsu, M. Ohara-Imaizumi, Y. Nakamichi, T. Kikuta, and C. Nishiwaki Imaging docking and fusion of insulin granules induced by antidiabetes agents: sulfonylurea and glinide drugs preferentially mediate the fusion of newcomer, but not previously docked, insulin granules. Diabetes, October 1, 2006; 55(10): 2819 - 2825. [Abstract] [Full Text] [PDF]

				B. Kimmel and S. E. Inzucchi Oral Agents for Type 2 Diabetes: An Update Clin. Diabetes, April 1, 2005; 23(2): 64 - 76. [Abstract] [Full Text] [PDF]

				C. Abletshauser, P. Brunel, K.-H. Usadel, and M. Hanefeld Effect of nateglinide and glimepiride in reducing postprandial hyperglycaemia in patients with type 2 diabetes mellitus The British Journal of Diabetes & Vascular Disease, March 1, 2005; 5(2): 93 - 99. [Abstract] [PDF]

				J. Rosenstock, D. R. Hassman, R. D. Madder, S. A. Brazinsky, J. Farrell, N. Khutoryansky, and P. M. Hale Repaglinide Versus Nateglinide Monotherapy: A randomized, multicenter study Diabetes Care, June 1, 2004; 27(6): 1265 - 1270. [Abstract] [Full Text] [PDF]

				M. J. Abrahamson Optimal Glycemic Control in Type 2 Diabetes Mellitus: Fasting and Postprandial Glucose in Context Arch Intern Med, March 8, 2004; 164(5): 486 - 491. [Abstract] [Full Text] [PDF]

				R. R. Koski Oral Antidiabetic Agents: A Comparative Review Journal of Pharmacy Practice, February 1, 2004; 17(1): 39 - 48. [Abstract] [PDF]

				S. R. Salpeter, E. Greyber, G. A. Pasternak, and E. E. Salpeter Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis Arch Intern Med, November 24, 2003; 163(21): 2594 - 2602. [Abstract] [Full Text] [PDF]

				A. Sevinc Should Diabetic Patients Treated Long-term With Sulfonylureas Be Switched to Nateglinide? Arch Intern Med, July 28, 2003; 163(14): 1741 - 1741. [Full Text] [PDF]

				{blacktriangledown}Nateglinide and {blacktriangledown}repaglinide for type 2 diabetes? DTB, July 1, 2003; 41(7): 52 - 54. [Abstract] [Full Text] [PDF]

				S. Del Prato, R. J. Heine, L. Keilson, C. Guitard, S. G. Shen, and R. P. Emmons Treatment of Patients Over 64 Years of Age With Type 2 Diabetes: Experience from nateglinide pooled database retrospective analysis Diabetes Care, July 1, 2003; 26(7): 2075 - 2080. [Abstract] [Full Text] [PDF]

				J. E. Gerich Clinical Significance, Pathogenesis, and Management of Postprandial Hyperglycemia Arch Intern Med, June 9, 2003; 163(11): 1306 - 1316. [Abstract] [Full Text] [PDF]

				V. Fonseca, G. Grunberger, S. Gupta, S. Shen, and J. E. Foley Addition of Nateglinide to Rosiglitazone Monotherapy Suppresses Mealtime Hyperglycemia and Improves Overall Glycemic Control Diabetes Care, June 1, 2003; 26(6): 1685 - 1690. [Abstract] [Full Text] [PDF]

				R.M. Califf Insulin resistance: a global epidemic in need of effective therapies Eur. Heart J. Suppl., April 1, 2003; 5(suppl_C): C13 - C18. [Abstract] [PDF]

				C. Saloranta, C. Guitard, E. Pecher, P. de Pablos-Velasco, K. Lahti, P. Brunel, and L. Groop Nateglinide Improves Early Insulin Secretion and Controls Postprandial Glucose Excursions in a Prediabetic Population Diabetes Care, December 1, 2002; 25(12): 2141 - 2146. [Abstract] [Full Text] [PDF]

				H. E Lebovitz Review: Type 2 diabetes: how far have we come? The British Journal of Diabetes & Vascular Disease, November 1, 2002; 2(6): 446 - 449. [Abstract] [PDF]

				D. M. Nathan Initial Management of Glycemia in Type 2 Diabetes Mellitus N. Engl. J. Med., October 24, 2002; 347(17): 1342 - 1349. [Full Text] [PDF]

				J. B. Meigs, D. M. Nathan, R. B. D'Agostino Sr, and P. W.F. Wilson Fasting and Postchallenge Glycemia and Cardiovascular Disease Risk: The Framingham Offspring Study Diabetes Care, October 1, 2002; 25(10): 1845 - 1850. [Abstract] [Full Text] [PDF]

				C. Saloranta, K. Hershon, M. Ball, S. Dickinson, and D. Holmes Efficacy and Safety of Nateglinide in Type 2 Diabetic Patients with Modest Fasting Hyperglycemia J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4171 - 4176. [Abstract] [Full Text] [PDF]

				J. Rosenstock, S. G. Shen, M. R. Gatlin, and J. E. Foley Combination Therapy With Nateglinide and a Thiazolidinedione Improves Glycemic Control in Type 2 Diabetes Diabetes Care, September 1, 2002; 25(9): 1529 - 1533. [Abstract] [Full Text] [PDF]

				Y. Miyazaki, M. Matsuda, and R. A. DeFronzo Dose-Response Effect of Pioglitazone on Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes Diabetes Care, March 1, 2002; 25(3): 517 - 523. [Abstract] [Full Text] [PDF]

				S. E. Inzucchi Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review JAMA, January 16, 2002; 287(3): 360 - 372. [Abstract] [Full Text] [PDF]

				J. R. White Jr. and R. K. Campbell Recent Developments in the Pharmacological Reduction of Blood Glucose in Patients With Type 2 Diabetes Clin. Diabetes, October 1, 2001; 19(4): 153 - 159. [Abstract] [Full Text] [PDF]

				T. P. Erlinger and F. L. Brancati Postchallenge Hyperglycemia in a National Sample of U.S. Adults With Type 2 Diabetes Diabetes Care, October 1, 2001; 24(10): 1734 - 1738. [Abstract] [Full Text] [PDF]

				P. A. Hollander, S. L. Schwartz, M. R. Gatlin, S. J. Haas, H. Zheng, J. E. Foley, and B. E. Dunning Importance of Early Insulin Secretion: Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes Diabetes Care, June 1, 2001; 24(6): 983 - 988. [Abstract] [Full Text]